Table 1. Therapeutic agents undergoing clinical trials for stroke treatment.

Updated from Small DL et al., 2002 (4).

Drug Class	Drug
Drugs for improving blood flow
Antithrombotic	Heparin, Nadroparin, Tinzaparin, Danaparoid
Anti-platelet	Aspirin, Abciximab
Fibrinogen depleting	Ancrod
Improve capillary flow	Pentoxifylline
Thrombolytics	Pro-urokinase, Tissue plasminogen activator, Streptokinase, Urokinase
Drugs to protect brain tissue (neuroprotective agents)
Calcium channel blockers	Nimodipine, Flunarizine
Free radical scavengers-antioxidants	Ebselen, Tirilazad, NYP-059
GABA agonists	Clomethiazole
AMPA antagonists	GYKI 52466, NBQX, YM90K, YM872, ZK-200775 (MPQX)
Kainate antagonist	SYM 2081
Competitive NMDA antagonists	CGS 19755 (Selfotel)
NMDA channel blockers	Aptiganel (Cerestat), Dextrorphan, Dextromethorphan
Magnesium	Memantine, MK-801, NPS 1506, AR-R15896AR, HU-211, Remacemide
Glycine site antagonists	ACEA 1021, GV 150526
Polyamine site antagonists	Eliprodil, Ifenprodil
Growth factors	Fibroblast Growth factor (bFGF)
Leukocyte adhesion inhibitor	Anti-ICAM antibody (Enlimonab), Hu23F2G
Nitric oxide inhibitor	Lubeluzole
Opioid antagonists	Naloxone, Nalmefene
Phosphatidylcholine precursor	Citicoline (CDP-choline)
Serotonin agonists	Bay × 3072
Sodium channel blockers	Fosphenytoin, Lubeluzole, 619C89
Potassium channel opener	BMS-204352